psoriatic arthritis drugs
Mar 13, 2026
SOTYKTU Expands Its Reach as Bristol Myers Squibb Lands Key Approval in Psoriatic Arthritis
Summary Bristol Myers Squibb’s SOTYKTU has received FDA approval for adults with active psoriatic arthritis, becoming the first and only TYK2 inhibitor authorized for this indication. The drug extends its reach beyond its 2022 approval for moderate-to-severe plaque psoriasis, reinforcing BMS’s bid to b...
Read More...
Jun 17, 2025
Celltrion Announces FDA Nod for New STEQEYMA Presentation to Broaden Pediatric Use; CSL’s ANDEMBRY Gets FDA Nod as First Factor XIIa Inhibitor for Hereditary Angioedema; Ocugen’s OCU410ST Cleared by FDA to Begin Phase II/III Trial in Stargardt Disease; Milestone Pharmaceuticals Submits FDA Response for CARDAMYST in PSVT; AbbVie’s MAVYRET Approved by FDA as First and Only Therapy for Acute Hepatitis C
Celltrion Announces FDA Approval of New STEQEYMA Presentation, Expanding Pediatric Dosing Options Celltrion, Inc. has announced that the FDA has approved an additional presentation of STEQEYMA (ustekinumab-stba), a biosimilar to STELARA, in a 45mg/0.5mL single-dose vial for subcutaneous injection. This new formu...
Read More...
Oct 28, 2022
HUMIRA Biosimilars in the US: The Talk of the Psoriatic Arthritis Treatment Market
Psoriatic arthritis (PsA) is a type of chronic inflammatory arthritis that affects approximately 1 in every 10 people with psoriasis. According to the National Psoriasis Foundation, psoriasis is most common in adults aged 30 to 50. However, psoriatic arthritis can develop at any age, including children. Accordin...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
